Partager cette page

Sr. Scientist, Antibody Discovery, Société CILOA

CILOA, a Biotech located in south of France, with a disruptive technology in the use of challenging proteins as immunogens is looking for an energetic Research Scientist with strong hands-on experience in immunology, cellular and molecular biology for a permanent position (CDI). Using state-of-the-art technologies, he will isolate antibody cDNA from single B cells. He will create a platform aiming to develop therapeutic antibodies. His success will contribute to our mission in the development of innovative therapeutics targeting so-called “undruggable” proteins involved in several types of pathologies.


Opportunities to break new ground trusting you with responsibility early on and allowing you to fulfill your ambitions, and to draw your own career map that is responsive to your aspirations and priorities in life. Bring your imagination and skills to life!

Mission and key responsibilities:

  • Create and lead the platform of antibody generation using single B cell cloning strategy.

  • Design, execute and analyze experimental studies, propose creative solutions to troubleshoot problems, and proactively research new methods to improve processes.

  • Perform molecular and cellular biology experiments, including RT-PCR, PCR, recombinant DNA cloning, plasmid preps, bacterial transformation, mammalian cell culture, mammalian transfection for transient protein expression.

  • Conduct different assays: FACS, ELISA, Western blotting, BLI and SPR based Ab screening.

  • Collaborate and support other team members effectively to enhance productivity of the group and accomplish organizational goals.

  • Assist with process improvements by thinking critically about the design and execution of experiments, including automation, and SOP development.

  • With strong attention to detail, perform excellent record-keeping, time-management and organization to achieve group and company deliverables.

Required experience and skills:

  • Ph.D. in Molecular Biology, Immunology, or Cell Biology, with a minimum of 3+ years required; a post doc in relevant field a plus.

  • Experience in antibody generation strategies is desired; antibody engineering, optimization of effector function, affinity and biophysical properties a plus.

  • Experience with B cell biology with a solid background in mouse and human adaptive immune system, and in B/T cell differentiation.

  • Technical proficiency in molecular biology.

  • Mastery of sterile cell culture is a must.

  • Experience in multi-parameter/multi-color flow cytometry is desired. Knowledge of Flow cytometry based cell sorting is a plus.

  • Hands-on experience in antibody discovery methods, including advanced B-cell cloning is desired; hybridoma techniques, phage, yeast or/and mammalian display and other display technologies a plus.

  • Expertise in therapeutic antibody is desirable but not essential.

  • Familiarity with HTP automated recombinant protein expression is a plus.

  • Demonstrated ability to be proactive, diligent and reliable to meet deadlines. Excellent organization and planning skills.

  • Must be highly collaborative, team-oriented, yet with the ability to work independently.

  • Excellent interpersonal, verbal and written communication skills are required. Attention to detail and analytical.

  • Fluent English both written and verbal; French is a plus.

Applications should include: Send at contact(at)ciloa(dot)fr, a cover letter, CV, statement of research interests, and contact information for potential references.


Abreos Biosciences, biotech californienne basée à San Diego, s’implante à Marseille et engage un partenariat de recherche avec l’IPC sur le monitoring des biomédicaments

Pionnière dans le dosage personnalisé des biomédicaments, Abreos développe des tests, applicables en laboratoire ou au chevet du patient, mesurant les niveaux sanguins de biomédicaments (incluant les biosimilaires), grâce à la la technologie VeritopeTM

Abreos a engagé un partenariat de recherche avec l’Institut Paoli-Calmettes (IPC) pour étudier les niveaux sanguins des biomédicaments chez les patients atteints de cancers, et ainsi accélérer le développement de stratégies de dosage adaptées à chaque patient, pour maximiser l’efficacité du traitement, et réduire les effets secondaires et les coûts associés à la thérapie.
Abreos annonce également la création de sa filiale française, Abreos France, qui, avec le soutien d’Eurobiomed,  a déjà établi son laboratoire au sein de l’IPC et a recruté du personnel, avec qui chercheurs et cliniciens de l’Institut vont travailler étroitement. 

Cette implantation est un résultat probant du partenariat Eurobiomed / Biocom.

En savoir plus sur le site d'internet d'Abreos